Glioblastoma — frontier options in Georgia
15 open options
- TRIALPHASE2RECRUITING
ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
ACT001 — 20 sites
- TRIALPHASE1RECRUITING
Atovaquone Combined With Radiation in Children With Malignant Brain Tumors
Atovaquone · Radiation Therapy — 2 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
Biopsy Procedure · Magnetic Resonance Imaging · Radiation Therapy — 127 sites
- TRIALPHASE2RECRUITING
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging · Fluciclovine F18 · Gadolinium-Chelate — 18 sites
- TRIALPHASE3RECRUITING
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
SonoCloud-9 (SC9) · Carboplatin · Lomustine — 55 sites
- TRIALPHASE1 / PHASE2RECRUITING
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Biospecimen Collection · Magnetic Resonance Imaging · Placebo Administration — 36 sites
- TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 57 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Oral repotrectinib (TPX-0005) — 68 sites
- TRIALNARECRUITING
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors
Magnetic Resonance Spectroscopic Imaging · Proton Therapy — 3 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Temozolomide · Lomustine · Regorafenib — 63 sites
- TRIALPHASE1 / PHASE2RECRUITING
Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma
Verteporfin — 1 site
- TRIALPHASE1RECRUITING
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
Biospecimen Collection · Computed Tomography · Intensity-Modulated Radiation Therapy — 43 sites
- TRIALPHASE1RECRUITING
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
Indoximod · Ibrutinib · Cyclophosphamide — 1 site
- TRIALPHASE1RECRUITING
ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
ONC206 · Standard of Care Radiation Therapy · Optional Proton (1H) MR spectroscopy (MRS) — 7 sites
- TRIALEARLY_PHASE1NOT_YET_RECRUITING
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
avutometinib and defactinib for 3 weeks on/1 week off · MGMT-unmethylated GBM with Radiation — 3 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.